[HTML][HTML] Comparing the cost-effectiveness of sintilimab+ pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with …
Y Shi, D Qian, Y Li, W Chen, M Bo… - Translational Cancer …, 2023 - ncbi.nlm.nih.gov
Background Pemetrexed plus platinum alone is the conventional first-line therapy for locally
advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable …
advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable …
Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell …
H Liu, Y Wang, Q He - Health Economics Review, 2022 - Springer
Objective In frst-line treatment of advanced or metastatic nonsquamous non-small-cell lung
cancer (NSCLC), the ORIENT-11 study demonstrated a signifcant progression-free survival …
cancer (NSCLC), the ORIENT-11 study demonstrated a signifcant progression-free survival …
OP13 Cost-Effectiveness Analysis Of Sintilimab Plus Chemotherapy For The First-Line Treatment Of Non-Squamous Non-Small Cell Lung Cancer: Societal …
F Li, Y Yang, D Xiao, Y Chen - International Journal of Technology …, 2023 - cambridge.org
IntroductionSintilimab is an IgG4 anti-programmed cell death protein 1 (PD-1) antibody that
has a high-affinity blocking interaction with PD-1 and its ligands. The updated ORIENT-11 …
has a high-affinity blocking interaction with PD-1 and its ligands. The updated ORIENT-11 …
Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective
F Li, Y Chen, D Xiao, S Jiang, Y Yang - Advances in Therapy, 2024 - Springer
Introduction The updated ORIENT-11 study demonstrated that sintilimab, when combined
with chemotherapy, had promising survival advantage compared to standard chemotherapy …
with chemotherapy, had promising survival advantage compared to standard chemotherapy …
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 …
L Zhang, Z Wang, J Fang, Q Yu, B Han, S Cang… - Lung Cancer, 2022 - Elsevier
Abstract Objectives In ORIENT-11, first-line sintilimab+ pemetrexed-platinum significantly
improved PFS compared with placebo+ pemetrexed-platinum in patients with advanced …
improved PFS compared with placebo+ pemetrexed-platinum in patients with advanced …
Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a …
M Liao, S Kang - Expert Review of Pharmacoeconomics & …, 2024 - Taylor & Francis
Objectives The current study aimed to evaluate the cost-effectiveness of sintilimab versus
docetaxel as second-line treatment for patients with advanced or metastatic squamous non …
docetaxel as second-line treatment for patients with advanced or metastatic squamous non …
Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
P Chen, X Wang, S Zhu, H Li, M Rui, Y Wang… - Frontiers in Public …, 2022 - frontiersin.org
Background and objective Sintilimab has superior efficacy and safety in patients with
advanced or metastatic squamous non-small cell lung cancer (NSCLC), but its cost …
advanced or metastatic squamous non-small cell lung cancer (NSCLC), but its cost …
Cost-effectiveness analysis of sintilimab+ chemotherapy versus camrelizumab+ chemotherapy for the treatment of first-line locally advanced or metastatic …
M Rui, Z Fei, Y Wang, X Zhang, A Ma… - Journal of medical …, 2022 - Taylor & Francis
Background and objective Sintilimab is a selective PD-1 inhibitor with efficacy in advanced
or metastatic nonsquamous non-small-cell lung cancer (NSCLC) patients. This study …
or metastatic nonsquamous non-small-cell lung cancer (NSCLC) patients. This study …
Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced or recurrent non-small cell lung cancer
H GAO, M HU, L JIA, F WU, Y HOU - China Pharmacy, 2022 - pesquisa.bvsalud.org
OBJECTIVE From the perspective of China'sh ealth service system, to ev aluate the cost-
effectiveness of sintilimab combined with chemotherapy in the first-line treatment of …
effectiveness of sintilimab combined with chemotherapy in the first-line treatment of …
Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung …
Objectives Retrospective subgroup analysis in JMDB study indicates that the between-arm
differences in overall survival (OS) in the East Asian subgroup were consistent with those …
differences in overall survival (OS) in the East Asian subgroup were consistent with those …
相关搜索
- cost effectiveness societal perspective
- cost effectiveness pemetrexed and platinum
- cost effectiveness chinese patients
- cost effectiveness lung cancer
- nonsquamous nsclc pemetrexed and platinum
- cost effectiveness nonsquamous nsclc
- pemetrexed cisplatin chinese patients
- efficacy and safety chinese patients
- cost effectiveness economic evaluation
- lung cancer economic evaluation
- gemcitabine cisplatin chinese patients